Journal article
Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy
- Abstract:
-
Aims Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced oxidative stress and energy depletion. Unbound/loosely bound tissue copper II ions are powerful catalysts of oxidative stress and inhibitors of antioxidants. Trientine is a highly selective copper II chelator. In preclinical and clinical studies in diabetes, trientine is associated with reduced LVH and fibrosis, and improved mitochondrial function and energy metabolism. Trientine was associated with improvements in cardiac structure and function in an open-label study in patients with HCM.
Methods The Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyopathy (TEMPEST) trial is a multicentre, double-blind, parallel group, 1:1 randomised, placebo-controlled phase II trial designed to evaluate the efficacy and mechanism of action of trientine in patients with HCM. Patients with a diagnosis of HCM according to the European Society of Cardiology Guidelines and in New York Heart Association classes I–III are randomised to trientine or matching placebo for 52 weeks. Primary outcome is change in left ventricular (LV) mass indexed to body surface area, measured using cardiovascular magnetic resonance. Secondary efficacy objectives will determine whether trientine improves exercise capacity, reduces arrhythmia burden, reduces cardiomyocyte injury, improves LV and atrial function, and reduces LV outflow tract gradient. Mechanistic objectives will determine whether the effects are mediated by cellular or extracellular mass regression and improved myocardial energetics.
Conclusion TEMPEST will determine the efficacy and mechanism of action of trientine in patients with HCM.
Trial registration numbers NCT04706429 and ISRCTN57145331.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1008.1KB, Terms of use)
-
- Publisher copy:
- 10.1136/heartjnl-2022-322271
- Publisher:
- BMJ Publishing Group
- Journal:
- Heart More from this journal
- Volume:
- 109
- Issue:
- 15
- Pages:
- 1175-1182
- Place of publication:
- England
- Publication date:
- 2023-05-03
- Acceptance date:
- 2023-03-14
- DOI:
- EISSN:
-
1468-201X
- ISSN:
-
1355-6037
- Pmid:
-
37137675
- Language:
-
English
- Keywords:
- Pubs id:
-
1340565
- Local pid:
-
pubs:1340565
- Deposit date:
-
2024-01-19
Terms of use
- Copyright holder:
- Farrant et al
- Copyright date:
- 2023
- Rights statement:
- © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record